(NASDAQ: BOLT) Bolt Biotherapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 26.44%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.98%.
Bolt Biotherapeutics's earnings in 2025 is -$50,713,000.On average, 7 Wall Street analysts forecast BOLT's earnings for 2025 to be -$45,010,508, with the lowest BOLT earnings forecast at -$48,756,873, and the highest BOLT earnings forecast at -$41,114,426. On average, 7 Wall Street analysts forecast BOLT's earnings for 2026 to be -$69,405,067, with the lowest BOLT earnings forecast at -$137,316,809, and the highest BOLT earnings forecast at -$25,192,663.
In 2027, BOLT is forecast to generate -$47,536,108 in earnings, with the lowest earnings forecast at -$74,489,666 and the highest earnings forecast at -$2,499,112.